Lenalidomide Maintenance Therapy Outperforms Observation in Newly Diagnosed Multiple MyelomaDecember 11th 2017
Continuous lenalidomide therapy improves outcomes among patients with newly diagnosed myeloma who are not autologous stem cell transplant candidates, according to findings from a large phase III clinical trial.
FDA Grants Durvalumab Breakthrough Designation for Bladder CancerFebruary 19th 2016
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational human IgG1 monoclonal antibody durvalumab (MEDI4736) for patients with inoperable or metastatic urothelial bladder cancer that is programmed-cell-death-ligand 1 (PD-L1)-positive and refractory to platinum-based treatment.
Markers in Medullary Thyroid Cancer May Signal Metastasis, Vandetanib ResponseOctober 22nd 2015
Researchers in Germany appear to have identified a gene-expression signature associated with metastasis in sporadic medullary thyroid cancer and prognostic molecular tumor markers of medullary thyroid cancer response to vandetanib therapy.